Humana Inc vs Innodata Inc — how do they compare? Humana Inc trades at $450.7 (market cap $46.49B), while Innodata Inc trades at $62.06 (market cap $2.10B). The key difference: Humana Inc is far larger — about 22.1× Innodata Inc's market cap, and Humana Inc pays a 0.91% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Innodata Inc for 19 Days on average.
| HUM | INOD | |
|---|---|---|
Market Cap | $46.49B | $2.10B |
Volume | 2,567,704 | 989,493 |
Sector | Health | Technology |
52-Week High | $409.85 | $121.50 |
52-Week Low | $163.67 | $34.45 |
Typical Hold Time | 53 Days | 19 Days |
Enterprise Value | $53.84B | $1.86B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
INOD trades at $63.42, down 4.26% today but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The company shows robust profitability with 42.7% gross margins and 37.7% ROE, while technical indicators suggest a bullish trend despite recent pullback. Recent developments include expansion into motion-capture AI labs and strategic board appointments, positioning the company for continued AI infrastructure growth.
The outlook remains positive with analyst consensus favoring buy ratings (66.7%) and projected revenue growth to $317M in 2026. Key risks include premium valuation metrics (P/E 47.4) and customer concentration concerns, but strong cash flow generation and expanding AI service offerings provide growth catalysts for investors seeking exposure to the data engineering sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →